Key Highlights from the 2025 ESG Report

• Strengthened Corporate Governance: Biocytogen has deepened the professionalization, standardization, and internationalization of its governance structure, following its stable dual listing on the STAR Market (Shanghai) and Hong Kong Stock Exchange. Notably, the company abolished its Board of Supervisors, transferring oversight responsibilities to the Audit Committee, thereby streamlining decision-making and enhancing transparency.
• Robust ESG Strategy and Board Oversight: The Board of Directors has direct responsibility for ESG strategy, including climate risk integration into overall risk management. The company has identified 22 material ESG issues through systematic stakeholder engagement and internal analysis.
• Operational Excellence and Compliance: Biocytogen has embedded the philosophy of “Quality is Our Lifeline” throughout its R&D, production, and service chains. Stringent quality control and compliance measures are in place, particularly relevant for overseas expansion, intellectual property, and data security.
• Substantial R&D Investment: In 2025, R&D investment reached RMB 0.438 billion, constituting 31.77% of total expenditure, with 31.19% of employees in R&D roles. 27 new patents were granted, and cumulative patents reached 206, including a strong international portfolio.
• Strong Financial and Environmental Performance: Operating revenue was RMB 1.379 billion, with total assets at RMB 3.724 billion. ESG metrics show 61,783.41 MWh electricity consumption, 17,417.66 tCO₂e GHG emissions, and 85,757 tonnes of water consumption, with continual efforts to minimize environmental footprint.
• Zero Major Legal or Compliance Incidents: There were no significant breaches of environmental, anti-corruption, or employment laws, nor any material product recalls or data/privacy incidents in 2025. All Board members and employees received anti-corruption training (100% coverage).
• Comprehensive Risk Management: The company has formalized a systematic risk management framework, with regular reviews and updates to key policies and dynamic assessment of strategic, financial, operational, and compliance risks.

Items Potentially Price Sensitive for Shareholders

• Governance Restructuring: The abolition of the Board of Supervisors and transfer of its functions to the Audit Committee represents a major overhaul, reducing governance layers and potentially enhancing responsiveness and transparency. This could be seen as a step towards international best practice and may positively influence investor confidence and share valuation.
• Material ESG Integration and Climate Risk Disclosure: The Board’s direct oversight and the establishment of ESG targets (GHG, water, waste) align Biocytogen with global capital market expectations, potentially improving ESG ratings and attracting international institutional investors. The company’s proactive stance on climate risk, with scenario analysis and physical/transition risk mapping, is designed to mitigate future regulatory and market risks.
• Intellectual Property Expansion: The continued growth in patents (27 new, totaling 206) demonstrates innovation capacity and could support future licensing income and competitive advantage, affecting medium- to long-term value.
• R&D Investment and Talent Retention: Maintaining R&D investment at nearly one-third of total expenditure and high R&D staff ratio are positive signals for sustained innovation and future pipeline growth, which are critical valuation drivers in the biopharmaceutical sector.
• Absence of Material Compliance or Environmental Incidents: The clean compliance record, especially in a sector under stringent regulation, reduces legal and reputational risk, providing reassurance to investors.
• Climate and Supply Chain Risk Preparedness: The company identified several physical (e.g., extreme weather at Beijing HQ, Jiangsu, Boston sites) and transition risks (e.g., carbon compliance in China, US/EU disclosure mandates), and is actively investing in mitigation (e.g., renewable energy procurement, energy-saving retrofits). This forward-looking risk management could reduce future earnings volatility.

Detailed Developments Investors Should Watch

Governance and Organizational Changes

• Streamlined governance with the abolition of the Board of Supervisors; enhanced role of the Audit Committee.
• Board diversity: 44% female directors, average age 54, with expertise across pharmaceuticals, management, investment, and law.
• In 2025, the company held two general meetings and 10 Board meetings (100% attendance), reflecting strong engagement.

Risk and Compliance Management

• Comprehensive risk management system spanning strategic, financial, operational, and compliance risk, with dynamic policy updates (e.g., revised authorization and gift management rules).
• Whistleblower protection and reward mechanisms for anti-corruption reporting, with no material bribery or fraud cases.
• All employees and Board members underwent anti-corruption training and signed commitments.

ESG Performance and Climate Action

• Board-level climate risk oversight, with scenario analysis identifying acute and chronic risks (e.g., extreme weather, regulatory changes) and opportunities (e.g., low-carbon technology, new animal model markets).
• Annual GHG emissions (Scope 1 and 2): 17,417.66 tCO₂e, with targets to reduce emissions, water, and energy use.
• Significant investment in renewable energy (solar/PV: 39,937.8 MWh) and water-saving infrastructure.
• No environmental violations, remediation orders, or major penalties in 2025.

Innovation, R&D, and Intellectual Property

• R&D investment at RMB 0.438 billion (31.77% of expenditure); 450 R&D staff (31.19% of employees); 27 new patents granted in 2025; 206 cumulative patents (107 domestic, 99 overseas).
• Continued rollout of the proprietary RenMice® platform, with expansion into emerging disease models related to climate change.
• Comprehensive IP protection, with no infringement penalties or major data leaks reported in 2025.

Talent and Social Responsibility

• Total employees: 1,443, with 71% female and 100% training coverage.
• Market-competitive remuneration, clear advancement pathways, and robust health and safety programs (no work-related fatalities, comprehensive OHS training).
• Strong supplier management and fair treatment for SMEs; no overdue payables to small and medium suppliers.

Conclusion: Outlook for Investors

Biocytogen’s 2025 ESG Report signals a company maturing rapidly in its governance, compliance, and ESG risk management—key factors for long-term value in a globally competitive biopharma sector. The strategic overhaul of governance, focus on innovation, clean compliance record, active climate risk management, and robust talent pipeline could positively affect the company’s market perception, potentially enhancing its share value and attractiveness to institutional investors.

Investors should closely monitor the company’s execution on its climate and ESG targets, continued expansion of its intellectual property portfolio, and any future governance reforms or risk events that could impact its growth trajectory or valuation.